FLAT 15% MEDICARE REBATE FOR BRANDNAMES ADOPTED BY WAYS & MEANS COULD BE VIABLE, ATTRACTIVE ALTERNATIVE FOR BRAND FIRMS; PRYOR SEEKS 17% BRAND REBATES
Executive Summary
The 15% flat rebate for brandname products adopted by the House Ways & Means Committee on June 21 could cost the brandname sector as much as $11 bil. between 1997-2003 in rebates on drugs for the over-65 population but it also could create three major areas of savings for brand marketers.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth